These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 10860896)
21. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients. de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Burman WJ; Gallicano K; Peloquin C Clin Infect Dis; 1999 Mar; 28(3):419-29; quiz 430. PubMed ID: 10194057 [No Abstract] [Full Text] [Related]
24. New developments in antiretroviral treatment. Sadovsky R Am Fam Physician; 1999 Dec; 60(9):2663, 2666. PubMed ID: 10605997 [No Abstract] [Full Text] [Related]
25. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. Pinheiro Edos S; Antunes OA; Fortunak JM Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246 [TBL] [Abstract][Full Text] [Related]
26. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903 [TBL] [Abstract][Full Text] [Related]
27. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
28. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083 [TBL] [Abstract][Full Text] [Related]
30. Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection. Zala C; Rouleau D; Montaner JS Clin Infect Dis; 2000 Jun; 30 Suppl 2():S143-50. PubMed ID: 10860899 [TBL] [Abstract][Full Text] [Related]
32. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients? Cuzin L; Allavena C; Morlat P; Dellamonica P AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976 [TBL] [Abstract][Full Text] [Related]
35. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. van Praag RM; van Heeswijk RP; Jurriaans S; Lange JM; Hoetelmans RM; Prins JM Clin Infect Dis; 2001 Oct; 33(8):e91-2. PubMed ID: 11565093 [TBL] [Abstract][Full Text] [Related]
36. [New antiretroviral agents]. Roca B; Simón E An Med Interna; 1998 Nov; 15(11):606-14. PubMed ID: 9882861 [TBL] [Abstract][Full Text] [Related]
37. [Drugs active against retroviruses]. Brun-Vézinet F; Descamps D Rev Prat; 1997 Mar; 47(6):631-8. PubMed ID: 9183937 [TBL] [Abstract][Full Text] [Related]
39. Bridging the gap. Bringing new antiretroviral medications into the clinic. Williams A Adv Nurse Pract; 1999 Jan; 7(1):24-30; quiz 31-2. PubMed ID: 10030167 [TBL] [Abstract][Full Text] [Related]